

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

- 1.(currently amended) ~~The PTPRK_{Gly677}Arg682~~ An isolated immunogenic peptide consisting of the amino acid sequence of SEQ ID NO: 1.
- 2.(currently amended) A monoclonal or polyclonal antibody, or an active fragment thereof, which selectively binds the isolated peptide of claim 1.
- 3.(currently amended) An isolated nucleic acid molecule encoding the isolated peptide of claim 1.
- 4.(original) An expression vector carrying the nucleic acid molecule of claim 3.
- 5.(original) A host cell containing the vector of claim 4.
6. (currently amended) An isolated CD4+ T lymphocyte able to selectively recognize and bind ~~the~~ an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1 associated to a HLA-Class II molecule.

7.(original) A T lymphocyte according to claim 6, which selectively recognizes and binds a peptide/HLA-DR β 1*1001 complex.

8. (previously presented) Antigen presenting cells carrying the peptide SEQ ID NO: 1 bound to a HLA-DR β 1*1001 molecule.

9. (currently amended) ~~Pharmaceutical~~ An immunogenic composition, comprising: containing the peptide an immunogenic peptide consisting of the amino acid sequence of SEQ ID NO: 1 or a nucleic acid molecule encoding [[it]] said immunogenic peptide, in admixture with ~~pharmaceutically acceptable~~ excipients.

10. (canceled)

11.(currently amended) A medicament ~~for the preventive or therapeutic treatment of cancer~~ comprising ~~one of peptide SEQ ID NO: 1~~ an immunogenic peptide consisting of the amino acid sequence of SEQ ID NO: 1, and nucleic acid molecules encoding [[it]] said immunogenic peptide.

12.(canceled)

13. (currently amended) A diagnostic composition comprising ~~peptide SEQ ID NO: 1~~ an immunogenic peptide consisting of the

amino acid sequence of SEQ ID NO: 1, or of a nucleic acid molecule
encoding [[it]] said immunogenic peptide.

14. (canceled)